Oncternal Therapeutics Inc (ONCT)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Oncternal Therapeutics, Inc. (ONCT) Q2 2024 Earnings Call Transcript
Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q2 2024 Earnings Call August 8, 2024 5:00 PM ET Company Participants Richard Vincent - Chief Financial Officer Jim Breitmeyer - President and Chief Executive Officer Salim Yazji - Chief Medical Officer Conference Call Participants Carl Byrnes - Northland Capital Markets Kemp Dolliver - Brookline Capital Markets Operator Greetings and welcome to the Oncternal Therapeutics Second Quarter 2024 Financial Results Call. [Operator Instructions] As a reminder, this conference is being recorded.
Oncternal Therapeutics (ONCT) Reports Q2 Loss, Tops Revenue Estimates
Oncternal Therapeutics (ONCT) came out with a quarterly loss of $2.89 per share versus the Zacks Consensus Estimate of a loss of $3.03. This compares to loss of $3 per share a year ago.
Oncternal Therapeutics Inc (ONCT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Oncternal Therapeutics Inc ever had a stock split?
Oncternal Therapeutics Inc Profile
| Biotechnology Industry | Healthcare Sector | James B. Breitmeyer CEO | NASDAQ (CM) Exchange | 68236P206 CUSIP |
| US Country | 27 Employees | - Last Dividend | 6 Dec 2016 Last Split | 3 Feb 2004 IPO Date |
Overview
Oncternal Therapeutics, Inc. is a progressive clinical-stage biopharmaceutical company that is focused on the development of novel oncology therapies for cancers that have a high unmet medical need. The company is devoted to advancing a diverse clinical pipeline with a focus on targeted treatments designed to address specific cancer pathways. Oncternal leverages its scientific expertise to identify and develop therapies that aim to improve the outcomes for patients facing limited treatment options. With its headquarters based in San Diego, California, the company is at the forefront of cancer research, developing strategic partnerships, and licensing agreements with prominent institutions to enhance its pipeline and accelerate development.
Products and Services
- **Zilovertamab**A humanized monoclonal antibody, zilovertamab, is designed to target and bind to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1). This binding is intended to interrupt cancer cell growth and survival pathways, providing a targeted approach to treating specific cancers. Currently, zilovertamab is being evaluated through clinical trials for its efficacy and safety in cancer patients.
- **ONCT-216**This small molecule therapy operates by inhibiting the biological activities of the ETS-family transcription factor oncoproteins. It disrupts the function of these proteins that are known to play a significant role in the development and progression of various cancers. ONCT-216 is in Phase 1/2 clinical trials, showcasing Oncternal Therapeutics' commitment to developing treatments that target the fundamental mechanisms of cancer.
- **ONCT-808**ONCT-808 is a type of chimeric antigen receptor T-cells (CAR-T) therapy, which is in Phase 1/2 clinical trial stages. This innovative approach involves engineering patients' T-cells to target and kill cancer cells expressing ROR1. The therapy is under investigation for its potential in treating hematologic malignancies and solid tumors, positioning it as a promising option for cancers known to express this particular receptor.
- **ONCT-534**A dual-action androgen receptor inhibitor, ONCT-534 is in the preclinical development stage. This product candidate is being developed to treat castration-resistant prostate and other androgen receptor-driven cancers. By inhibiting the androgen receptor, ONCT-534 aims to thwart the growth of cancer cells dependent on this pathway, showcasing Oncternal Therapeutics' expansive approach towards targeting cancer through various biological mechanisms.
Oncternal Therapeutics, Inc. maintains strategic licensing agreements with several prestigious institutions, including the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and the University of Tennessee Research Foundation. These partnerships underline the company's dedication to harnessing collective expertise and resources to advance cancer treatment and care.
